Brief: Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25
21/11/2024 01:13
Nov 21 (Reuters) - Mayne Pharma Group Ltd MYX.AX :
* EXPECTS GROWTH IN UNDERLYING EBITDA AND FREE CASH FLOW IN
FY25
* FOR JULY-OCT UNDERLYING EBITDA OF A$14.7M
* JUL-OCT REVENUE A$132.5 MILLION
Further company coverage: MYX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)